Study ID: Inc Research Cubist CDiff
Title:

Phase 3 Randomized Double Blinded Active Controlled study in Patients with Clostridium difficile infection

Description:

The purpose of this study is to find out if CB-183,315 (an antibiotic) rather than oral vancomycin is a better therapeutic agent for the treatment of CDAD (clostridium difficile associated diarrhea) in adults. This study will use the difference in clinical response rates at end-of-therapy (EOT) for results.

Location:
Fargo Region
Principal Investigator:
Paul Mariani MD
Disease:
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list